Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Department of Molecular and Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.
Gut. 2022 Aug;71(8):1515-1531. doi: 10.1136/gutjnl-2020-323916. Epub 2021 Sep 6.
The absent in melanoma 2 (AIM2) cytosolic pattern recognition receptor and DNA sensor promotes the pathogenesis of autoimmune and chronic inflammatory diseases via caspase-1-containing inflammasome complexes. However, the role of AIM2 in cancer is ill-defined.
The expression of AIM2 and its clinical significance was assessed in human gastric cancer (GC) patient cohorts. Genetic or therapeutic manipulation of AIM2 expression and activity was performed in the genetically engineered spontaneous GC mouse model, as well as human GC cell line xenografts. The biological role and mechanism of action of AIM2 in gastric tumourigenesis, including its involvement in inflammasome activity and functional interaction with microtubule-associated end-binding protein 1 (EB1), was determined in vitro and in vivo.
AIM2 expression is upregulated by interleukin-11 cytokine-mediated activation of the oncogenic latent transcription factor STAT3 in the tumour epithelium of GC mouse models and patients with GC. Genetic and therapeutic targeting of AIM2 in mice suppressed tumourigenesis. Conversely, AIM2 overexpression augmented the tumour load of human GC cell line xenografts. The protumourigenic function of AIM2 was independent of inflammasome activity and inflammation. Rather, in vivo and in vitro AIM2 physically interacted with EB1 to promote epithelial cell migration and tumourigenesis. Furthermore, upregulated expression of AIM2 and EB1 in the tumour epithelium of patients with GC was independently associated with poor patient survival.
AIM2 can play a driver role in epithelial carcinogenesis by linking cytokine-STAT3 signalling, innate immunity and epithelial cell migration, independent of inflammasome activation.
黑色素瘤 2(AIM2)胞质模式识别受体和 DNA 传感器缺失可通过包含半胱天冬酶-1 的炎性小体复合物促进自身免疫和慢性炎症性疾病的发病机制。然而,AIM2 在癌症中的作用尚不清楚。
评估了 AIM2 的表达及其在人类胃癌(GC)患者队列中的临床意义。在遗传工程自发 GC 小鼠模型以及人 GC 细胞系异种移植中,对 AIM2 的表达和活性进行了遗传或治疗操作。在体外和体内确定了 AIM2 在胃癌发生中的生物学作用和作用机制,包括其在炎性小体活性中的参与以及与微管相关末端结合蛋白 1(EB1)的功能相互作用。
白细胞介素 11 细胞因子介导的癌基因潜伏转录因子 STAT3 的激活可上调 GC 小鼠模型和 GC 患者肿瘤上皮中的 AIM2 表达。在小鼠中对 AIM2 的遗传和治疗靶向抑制了肿瘤发生。相反,AIM2 的过表达增加了人 GC 细胞系异种移植物的肿瘤负荷。AIM2 的促肿瘤发生功能与炎性小体活性和炎症无关。相反,AIM2 在体内和体外与 EB1 物理相互作用,促进上皮细胞迁移和肿瘤发生。此外,GC 患者肿瘤上皮中 AIM2 和 EB1 的上调表达与患者生存不良独立相关。
AIM2 可以通过连接细胞因子-STAT3 信号、先天免疫和上皮细胞迁移,在不激活炎性小体的情况下,在上皮细胞癌变中发挥驱动作用。